Beach 'may never be safe for swimming'
The beach at Heacham near Hunstanton has been classified as poor by the Environment Agency since 2021, with the cause of the problem being disputed among experts and locals.
After another "poor" result, Sandra Squire, cabinet member for environment at West Norfolk Council, admitted the coastal waters off Heacham may always have high levels of pollution.
Studies suggest 60% of the intestinal enterococci (IE) bacteria recorded in human and animal waste may be coming from seabirds, which visit The Wash in huge numbers throughout the year.
IE is the main bacteria causing the problems at Heacham, which is found in human and animal waste and, if ingested, can cause severe stomach upsets.
Scientists are yet to gather a full picture of the sources of poor water quality at Heacham, but sewage leaks/outfalls, agricultural run-off and dog waste are all cited as contributing factors.
Squire told a full council meeting that seabirds may always cause issues at Heacham.
"Sooner or later we may have to admit, if 60% of pollution is coming from the bird population, it may be that this area should not be for bathing," she said.
While DNA evidence suggests seabirds are a major cause, bacteria levels are highest in July and August, said the Local Democracy Reporting Service.
Squire suggested that increase could be due to numerous factors, ranging from increased tourism, less or more rainfall or due to birds breeding.
To better understand the problems, she called for year-round testing at Heacham, as currently it is only conducted in the summer months.
The meeting heard that Anglian Water has said its sewage works was nearing capacity and would not be able to cope with any more housing development.
Squire said: "If Anglian Water said they cannot cope, then nothing else should be connected to that sewage works.
"We all know what happens when they can't cope - we end up with sewage in our streets, our rivers and seas."
The Environment Agency told the BBC: "Pollution comes in many forms and from multiple sources, and the Environment Agency will continue to investigate poor water quality."
Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
Bird mess a factor as beach earns a 'brown flag'
Rising fees make beach huts 'hard to keep or sell'
Borough Council of King's Lynn & West Norfolk
Environment Agency
Local Democracy Reporting Service
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Common pill you can buy for pennies could ward off Alzheimer's
Omega fatty acids, found in certain fish or taken as a supplement, could potentially help ward off Alzheimer's disease in women, a new study suggests. Researchers found that lipids – fat molecules in the body – are different in women with Alzheimer's and those without. But they stressed that more work was needed to see whether 'shifting the lipid composition can influence the biological trajectory' of the disease. Scientists from Kings College London and Queen Mary University London, examined blood samples taken from 841 people, including 306 people with Alzheimer's; 165 with mild cognitive impairment and 370 healthy people. They discovered that there was a noticeable loss of unsaturated fats, including those that contain omega fatty acids, in the blood of women with Alzheimer's disease compared to healthy women, according to the study, which has been published in the journal Alzheimer's and Dementia: The Journal of the Alzheimer's Association. READ MORE: People urged to put bowl of water on windowsill as heatwave hits Wales READ MORE: Lucy Letby has 'new hope' as barrister prepares to submit appeal file They also noted a steep increase in lipids with saturation – also known as 'unhealthy lipids' – in women with Alzheimer's compared to women without. But there was no difference between these fat molecules between men with, and without, a diagnosis of Alzheimer's – which researchers say could help deepen knowledge about why more women than men are diagnosed with Alzheimer's disease. 'Women are disproportionately impacted by Alzheimer's disease and are more often diagnosed with the disease than men after the age of 80,' said senior author of the study Dr Cristina Legido-Quigley, from King's College London. One of the most surprising things we saw when looking at the different sexes was that there was no difference in these lipids in healthy and cognitively impaired men, but for women this picture was completely different. 'The study reveals that Alzheimer's lipid biology is different between the sexes, opening new avenues for research. Our study suggests that women should make sure they are getting omega fatty acids in their diet – through fatty fish or via supplements. 'However, we need clinical trials to determine if shifting the lipid composition can influence the biological trajectory of Alzheimer's Disease.' Dr Asger Wretlind, first author of the study from King's College London, said: 'Although this still warrants further research, we were able to detect biological differences in lipids between the sexes in a large cohort, and show the importance of lipids containing omegas in the blood, which has not been done before. 'The results are very striking and now we are looking at how early in life this change occurs in women.' Dr Julia Dudley, head of research at Alzheimer's Research UK, which funded the study along with LundbeckFonden, said: 'In the UK, two in three people living with dementia are women. 'This could be linked to living longer, or other risk factors like social isolation, education, or hormonal changes from the menopause being at play. While this study shows that women with Alzheimer's had lower levels of some unsaturated fats compared with men, further work is needed. 'This includes understanding the mechanisms behind this difference and finding out if lifestyle changes, including diet could have a role.' People can consume omega-3 fatty acids by eating fatty fish including salmon, mackerel or sardines, or by taking a supplement. It comes as a separate study found that children who had a diet rich in omega-3 fatty acids may have a reduced risk of short sightedness. The study, published in the British Journal of Ophthalmology, examined data on 1,005 Chinese children aged between six and eight years, including their eye sight and regular surveys about their diet. Overall 28% of children had myopia. Researchers from Hong Kong found that a higher consumption of omega-3 fatty acids was associated with a lower risk of the condition.
Yahoo
3 hours ago
- Yahoo
First new treatment for advanced bladder cancer in decades given green light
A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease, saying that until now, the treatment for advanced bladder cancer had not significantly changed since the 1980s. They said there had been real 'unmet need' for patients with advanced disease, with some 29% of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30%) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5% of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.
E&E News
8 hours ago
- E&E News
EPA air chief — a lung disease victim — pushes rollback of soot rule
EPA air chief Aaron Szabo was swift to stress his personal stake in the job at his Senate confirmation hearing in March. As a sufferer of the life-threatening lung disease cystic fibrosis, 'I have always been acutely aware of air quality,' Szabo told the Senate Environment and Public Works Committee. If confirmed, he added, 'I will work to ensure that we are mitigating traditional air pollution.' Instead, just weeks after narrowly winning Senate approval, Szabo is marching ahead with the rollback of a seminal air quality standard intended to better protect him and millions of other people with chronic respiratory illnesses. Advertisement In a court filing last week, he declared that the Trump administration has set next February as the target date for final replacement of the stricter soot exposure limit put in place last year during President Joe Biden's tenure.
